Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Milton PackerStefan D AnkerJaved ButlerGerasimos FilippatosStuart J PocockPeter CarsonJames JanuzziSubodh VermaHiroyuki TsutsuiMartina BrueckmannWaheed JamalKaren KimuraJanet SchneeCordula ZellerDaniel CottonEdimar BocchiMichael BöhmDong-Ju ChoiVijay ChopraEduardo ChuquiureNadia GiannettiStefan JanssensJian ZhangJose R Gonzalez JuanateySanjay KaulHans-Peter Brunner-La RoccaBela MerkelyStephen J NichollsSergio PerroneIleana PinaPiotr PonikowskiNaveed SattarMichele SenniMarie-France SerondeJindrich SpinarIain SquireStefano TaddeiChristoph WannerFaiez Zannadnull nullPublished in: The New England journal of medicine (2020)
Among patients receiving recommended therapy for heart failure, those in the empagliflozin group had a lower risk of cardiovascular death or hospitalization for heart failure than those in the placebo group, regardless of the presence or absence of diabetes. (Funded by Boehringer Ingelheim and Eli Lilly; EMPEROR-Reduced ClinicalTrials.gov number, NCT03057977.).